| Catalog No. | Size | Price (USD) |
| 10064-MM01-50 | 50 µL | $147.96 |
| 10064-MM01-100 | 100 µL | $251.64 |
| 10064-MM01-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-BACE1 Antibody, Mouse Monoclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human BACE1 Has cross-reactivity in ELISA with Mouse BACE1 / ASP2 No cross-reactivity in ELISA with Human ADAM15 and Human cell lysate (293 cell line) |
| Immunogen | Recombinant Human BACE1 protein (Catalog#10064-H08H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human BACE1 extracellular domain (rhBACE1; Catalog#10064-H08H; Met 1-Thr 457; NP_036236.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG1 Clone #1H6C2D4 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-ASP2 Antibody; Anti-BACE Antibody; Anti-HSPC104 Antibody; Anti-KIAA1149 Antibody
Background Information
| Full Name | beta-site APP-cleaving enzyme 1 |
| Description | Beta-site APP-cleaving enzyme 1 (BACE1) is an aspartic-acid protease important in the formation of myelin sheaths in peripheral nerve cells. In the brain, This protein is expressed highly in the substantia nigra, locus coruleus and medulla oblongata. Strong BACE1 expression has also been described in pancreatic tissue. BACE1 has a pivotal role in the pathogenesis of Alzheimer's disease. In Alzheimer's disease patients, BACE1 levels were elevated although mRNA levels were not changed. It has been found that BACE1 gene expression is controlled by a TATA-less promoter. The translational repression as a new mechanism controlling its expression. And the low concentrations of Ca(2+) (microM range) significantly increased the proteolytic activity of BACE1. Furthermore, BACE1 protein is ubiquitinated, and the degradation of BACE1 proteins and amyloid precursor protein processing are regulated by the ubiquitin-proteasome pathway. It has also been identified as the rate limiting enzyme for amyloid-beta-peptide (Abeta) production. |
| References |
|
